4Q25 Operating Loss Widens, Net Loss Swings to Deficit


  • Q4 2025 consolidated revenue: KRW 184,186 million, up 22.2% QoQ and 17.4% YoY.
  • Operating loss of KRW 51,610 million, widening from KRW 19,371 million in the previous quarter and slightly worse than KRW 50,776 million a year ago.
  • Net loss of KRW 56,405 million, swinging from a profit of KRW 21,083 million in Q3 and a loss of KRW 2,673 million in Q4 2024.
  • Full-year cumulative: Revenue KRW 651,368 million (+143.5% YoY), operating loss KRW 123,502 million (improved from -138,431 million), net loss KRW 56,173 million (slightly worse than -50,117 million).

KOSPI Filing Information


  • Filing: Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
  • Company: SK Bioscience (302440)
  • Submission: SK Bioscience Co.,Ltd
  • Receipt: 02-03-2026
  • Under KRX KOSPI Market Division